{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:09:31Z","timestamp":1794960571560,"version":"4.9.1"},"reference-count":66,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,6,17]],"date-time":"2018-06-17T00:00:00Z","timestamp":1529193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal anemia is a serious and common complication in hemodialysis (<jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>) patients. The introduction of erythropoiesis\u2010stimulating agents (<jats:styled-content style=\"fixed-case\">ESA<\/jats:styled-content>s) has dramatically improved hemoglobin levels and outcomes. Several interventional studies reported that excessive correction of anemia and the massive use of <jats:styled-content style=\"fixed-case\">ESA<\/jats:styled-content> can trigger cardiovascular disease (<jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content>), and consequently may worsen the prognosis of patients undergoing <jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>. Therefore, it has been widely recognized that large doses of <jats:styled-content style=\"fixed-case\">ESA<\/jats:styled-content> should be used with caution. An effective use of iron preparations is required to yield the optimal effect of <jats:styled-content style=\"fixed-case\">ESA<\/jats:styled-content>. It is well\u2010known that iron utilization is inhibited under pathological conditions, such as chronic inflammation, resulting in <jats:styled-content style=\"fixed-case\">ESA<\/jats:styled-content> resistance. It is postulated that a new class of therapeutic agents for renal anemia, hypoxia inducible factor prolyl hydroxylase (<jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PH<\/jats:styled-content>) inhibitors, will have beneficial treatment effects in patients on <jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>. <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content> is induced by hypoxia and promotes erythropoietin production. In the absence of a hypoxic state, <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content> is decomposed by the <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content> catabolic enzyme. <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PH<\/jats:styled-content> inhibitors inhibit this degrading enzyme and stimulate endogenous erythropoietin production via <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content> induction. Additionally, <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PH<\/jats:styled-content> inhibitors promote effective utilization of iron and raise erythropoietin to physiological concentrations. Accordingly, <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PH<\/jats:styled-content> inhibitors improve anemia and iron metabolism. It appears that this effect persists irrespective of chronic inflammatory conditions. <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PH<\/jats:styled-content> inhibitors do not overshoot erythropoietin above physiological concentrations like <jats:styled-content style=\"fixed-case\">ESA<\/jats:styled-content>s. Therefore, it is hypothesized that <jats:styled-content style=\"fixed-case\">HIF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PH<\/jats:styled-content> inhibitors would not increase the risk of <jats:styled-content style=\"fixed-case\">CVD<\/jats:styled-content> in patients undergoing <jats:styled-content style=\"fixed-case\">HD<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/sdi.12719","type":"journal-article","created":{"date-parts":[[2018,6,17]],"date-time":"2018-06-17T22:14:50Z","timestamp":1529273690000},"page":"599-606","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Anemia in conventional hemodialysis: Finding the optimal treatment balance"],"prefix":"10.1111","volume":"31","author":[{"given":"Takeshi","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Office for Promoting Medical Research Showa University Tokyo Japan"},{"name":"Division of Nephrology Department of Medicine Showa University Fujigaoka Hospital Yokohama Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence Fukushima Medical University Fukushima Japan"},{"name":"Department of Healthcare Epidemiology School of Public Health in the Graduate School of Medicine Kyoto University Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[{"name":"Division of Nephrology Department of Medicine Showa University Fujigaoka Hospital Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology Department of Medicine Showa University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2006.06.001"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.12.1401"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27699"},{"key":"e_1_2_9_5_1","first-page":"S192","article-title":"NKF\u2010DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation\u2010Dialysis Outcomes Quality Initiative","volume":"30","author":"NKF\u2010DOQI","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(01)70008-X"},{"key":"e_1_2_9_7_1","first-page":"S11","article-title":"KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease","volume":"47","author":"KDOQI","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"50","key":"e_1_2_9_8_1","first-page":"471","article-title":"KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target","volume":"2007","author":"KDOQI","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_9_9_1","first-page":"1","article-title":"KDIGO Clinical practice guidelines for anemia in chronic kidney disease","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.06.008"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft033"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-017-0114-y"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.03.023"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)01099-6"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.108"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.382"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015060673"},{"key":"e_1_2_9_18_1","first-page":"280","article-title":"Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study","volume":"35","author":"Pascual J","year":"1991","journal-title":"Clin Nephrol"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12122797"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr697"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390903"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn346"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010020173"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu272"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.5301\/jva.5000798"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1032"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00836.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005109"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04601007"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2012.07.014"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.07.014"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12155"},{"key":"e_1_2_9_34_1","first-page":"gfx269","article-title":"Increased mortality in haemodialysis patients administered high doses of erythropoiesis\u2010stimulating agents: A propensity score\u2010matched analysis","volume":"33","author":"P\u00e9rez\u2010Garc\u00eda R","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2014.1001281"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000477217"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft062"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143430"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005040423"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.275"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05390517"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014090922"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05170513"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft483"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12891"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-016-1299-z"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012121164"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.163"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft424"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.302"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw264"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007111181"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015030241"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111838"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111139"},{"key":"e_1_2_9_56_1","first-page":"1","article-title":"Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis\u2010stimulating agents","author":"Haase VH","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00404"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.892577"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000454818"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.06.030"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.035"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr410"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08161109"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05931108"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559484"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13433"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2300"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T19:40:26Z","timestamp":1694461226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,17]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/sdi.12719"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12719","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,17]]},"assertion":[{"value":"2018-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}